{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:54:26Z","timestamp":1762458866324},"reference-count":129,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.critrevonc.2010.09.003","type":"journal-article","created":{"date-parts":[[2010,12,18]],"date-time":"2010-12-18T09:29:08Z","timestamp":1292664548000},"page":"69-86","source":"Crossref","is-referenced-by-count":39,"title":["Mantle cell lymphoma: The promise of new treatment options"],"prefix":"10.1016","volume":"80","author":[{"given":"Andre","family":"Goy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2010.09.003_bib0005","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0010","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Ghielmini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0015","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11912-007-0053-9","article-title":"Mantle cell lymphoma: evolving novel options","volume":"9","author":"Goy","year":"2007","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0020","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0025","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0030","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0035","first-page":"1580","article-title":"High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma","volume":"90","author":"Vigouroux","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0040","first-page":"1275","article-title":"Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study","volume":"89","author":"Lefr\u00e8re","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0045","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"issue":"10 Suppl 8","key":"10.1016\/j.critrevonc.2010.09.003_bib0050","first-page":"49","article-title":"Management of mantle cell lymphoma","volume":"12","author":"Armitage","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0055","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.critrevonc.2005.10.001","article-title":"Treatment of mantle cell lymphoma: current approach and future directions","volume":"58","author":"Brody","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0060","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.biocel.2007.04.026","article-title":"The cellular origin of mantle cell lymphoma","volume":"39","author":"Bertoni","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0065","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10428190009053541","article-title":"Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients","volume":"39","author":"Romaguera","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0070","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.leu.2402073","article-title":"Molecular heterogeneity of splenic marginal zone lymphomas: analysis of mutations in the 5\u2019 non-coding region of the bcl-6 gene","volume":"15","author":"Mateo","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0075","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0080","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0085","doi-asserted-by":"crossref","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology, Non-Hodgkin's lymphomas. Version 3.2007. Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/nhl.pdf. Last accessed on March 12th 2008.","DOI":"10.2165\/00151234-200805520-00006"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0090","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1182\/blood-2007-10-118794","article-title":"Van Roosbroeck K, Posp\u00edsilov\u00e1 H, Minnei F, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas","volume":"111","author":"Wlodarska","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network","volume":"131","author":"Tiemann","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0100","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0105","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0110","doi-asserted-by":"crossref","unstructured":"Pott C, Hoster E, B\u00f6ttcher S, Siebert R, Klapper K, Delfau MH, et al. Molecular remission after combined immunochemotherapy is of prognostic relevance in patients with MCL: results of the randomized intergroup trials of the European MCL Network. Blood (ASH Annual Meeting Abstracts) 2008;112 [abstract 582].","DOI":"10.1182\/blood.V112.11.582.582"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0115","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0120","article-title":"Validation of the Mantle Cell Lymphoma Prognostic Index (MIPI): a valuable tool for risk stratification in mantle cell lymphoma","volume":"114","author":"Smith","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0125","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/bmt.2008.349","article-title":"High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen","volume":"43","author":"Magni","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"15S","key":"10.1016\/j.critrevonc.2010.09.003_bib0135","article-title":"The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVAD) alternating with rituximab-methotrexate-AraC (R-MTX-AraC)","volume":"28","author":"Mato","year":"2010","journal-title":"J Clin Oncol (ASCO Annual Meeting Abstracts)"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0140","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0145","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0150","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/jcp.2008.057455","article-title":"Correlation of cyclin D1 transcript levels, transcript type and protein expression with proliferation and histology among mantle cell lymphoma","volume":"61","author":"Shakir","year":"2008","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0155","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood-2009-12-257485","article-title":"Genome wide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma","volume":"116","author":"Leshchenko","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0160","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood-2007-06-093401","article-title":"Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma","volume":"111","author":"Ek","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.09.003_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/CBM-2009-0114","article-title":"ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia","volume":"6","author":"Trojani","year":"2010","journal-title":"Cancer Biomark"},{"issue":"4","key":"10.1016\/j.critrevonc.2010.09.003_bib0170","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fern\u00e0ndez","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0175","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.22093","volume":"107","author":"Nickenig","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0180","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefr\u00e8re","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0185","doi-asserted-by":"crossref","unstructured":"Hoster E, Unterhalt M, W\u00f6rmann B, D\u00fchrsen U, Metzner B, Eimermacher H, et al. The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial. Blood (ASH Annual Meeting Abstracts) 2008;112 [abstract 3049].","DOI":"10.1182\/blood.V112.11.3049.3049"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0190","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2010.09.003_bib0195","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.3816\/CLM.2007.s.034","article-title":"Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas","volume":"8","author":"Fayad","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0200","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Wisconsin Oncology Network. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0205","first-page":"425","article-title":"Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma","volume":"91","author":"de Guibert","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0210","doi-asserted-by":"crossref","unstructured":"Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, et al. RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): final results of a phase II study from the GELA. Blood (ASH Annual Meeting Abstracts) 2008; 112 [abstract 581].","DOI":"10.1182\/blood.V112.11.581.581"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0215","article-title":"Rituximab (R)+hyperCVAD alternating with R-methotrexate\/cytarabine after 9 years: continued high rate of failure-free survival in untreated mantle cell lymphoma (MCL)","volume":"112","author":"Romaguera","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0220","first-page":"265","article-title":"VcR-CVAD produces a high complete response rate in untreated mantle cell lymphoma: A Phase II Study from the Wisconsin Oncology Network","volume":"112","author":"Kahl","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0225","doi-asserted-by":"crossref","unstructured":"Kahl BS, Li H, Smith MR, Gascoyne RD, Paietta E, Advani R, Horning SJ. The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405\u2013A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. Blood (ASH Annual Meeting Abstracts) 2009; 114 [abstract 1661].","DOI":"10.1182\/blood.V114.22.1661.1661"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0230","doi-asserted-by":"crossref","unstructured":"LaCasce A, Vandergrift JL, Rodriguez MA, Crosby AL, Lepisto EM, Czuczman MS, et al. R-CHOP, followed by high dose therapy and autologous stem cell rescue (HDT\/ASCR), and R-HyperCVAD have equivalent progression-free survival and are superior to R-CHOP alone in younger patients with mantle cell lymphoma: a comparative effectiveness analysis from the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project. Blood (ASH Annual Meeting Abstracts) 2009; 114 [abstract 403].","DOI":"10.1182\/blood.V114.22.403.403"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0235","doi-asserted-by":"crossref","unstructured":"Feldman T, Mato AR, Zielonka T, Masood A, Goldberg S, Rowley SD, et al. Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT\/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell lymphoma (MCL). J Clin Oncol (ASCO Annual Meeting Abstracts) 2010; 28(15S) [abstract 8067].","DOI":"10.1200\/jco.2010.28.15_suppl.8067"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0240","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0245","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0250","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.2008.19.5032","article-title":"Progress in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0255","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/annonc\/mdn045","article-title":"Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies","volume":"19","author":"Martin","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0260","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0265","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0270","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0275","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","volume":"48","author":"Weide","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0280","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat A, von Gruenhagen U, Losem C, et al. Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 2009; 114 [abstract 405].","DOI":"10.1182\/blood.V114.22.405.405"},{"issue":"7","key":"10.1016\/j.critrevonc.2010.09.003_bib0285","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","article-title":"High anti-lymphoma activity of bendamustine\/mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"48","author":"Weide","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.critrevonc.2010.09.003_bib0290","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1080\/10428190400004521","article-title":"Bendamustine\/Mitoxantrone\/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study","volume":"45","author":"Weide","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"27","key":"10.1016\/j.critrevonc.2010.09.003_bib0295","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0300","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Vose JM, Kelly JL, Young F, Liesveld J, Armitage JO, et al. Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed\/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial. Blood (ASH Annual Meeting Abstracts) 2009; 114 [abstract 924].","DOI":"10.1182\/blood.V114.22.924.924"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0305","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood.V86.7.2463.2463","article-title":"Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders","volume":"86","author":"Tallman","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0310","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.leu.2402531","article-title":"Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia","volume":"16","author":"Robak","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0315","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/cncr.22196","article-title":"Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma","volume":"107","author":"Robak","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0320","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.1998.16.2.579","article-title":"Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas","volume":"16","author":"Decaudin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0325","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","article-title":"Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstr\u00f6m's macroglobulinemia, and mantle-cell lymphoma","volume":"17","author":"Foran","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0330","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/10428190109097721","article-title":"Cyclophosphamide\/fludarabine (CF) is active in the treatment of mantle cell lymphoma","volume":"42","author":"Cohen","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0335","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.23537","article-title":"Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group","volume":"113","author":"Inwards","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0340","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0345","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"issue":"18S","key":"10.1016\/j.critrevonc.2010.09.003_bib0350","article-title":"Mantle cell lymphoma (MCL): induction therapy with HyperCVAD\/high-dose methotrexate and cytarabine (M-C) (\u00b1rituximab) improves results of autologous stem cell transplant in first remission","volume":"24","author":"Vose","year":"2006","journal-title":"J Clin Oncol (ASCO Annual Meeting Abstracts)"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0355","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00277-006-0193-2","article-title":"The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma","volume":"86","author":"Ritchie","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0360","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose chemotherapy an in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0365","doi-asserted-by":"crossref","unstructured":"Vose J, Loberiza F, Bierman P, Bociek G, Armitage J. Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD\/High-dose methotrexate and cytarabine (M-C) (\u00b1rituximab) improves results of autologous stem cell transplant in first remission. J Clin Oncol (ASCO Annual Meeting Abstracts) 2006; 24(18S) [abstract 7511].","DOI":"10.1200\/jco.2006.24.18_suppl.7511"},{"issue":"6","key":"10.1016\/j.critrevonc.2010.09.003_bib0370","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1080\/10428190801923725","article-title":"Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma","volume":"49","author":"Till","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0375","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0380","doi-asserted-by":"crossref","unstructured":"Hosein PJ, Morgensztern D, Coleman F, Walker G, Escalon M, Rosenblatt J, et al. High remission rates and prolonged progression free survival in newly diagnosed patients with mantle cell lymphoma treated with R-MACLOIVAM-T. Blood (ASH Annual Meeting Abstracts) 2008; 112 [abstract 3597].","DOI":"10.1182\/blood.V112.11.3597.3597"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0385","doi-asserted-by":"crossref","unstructured":"Kolstad A, Laurell A, Andersen NS, Elonen E, Raty R, Pedersen LB, et al. 90Y-ibritumumab tiuxetan (Zevalin\u00ae)-BEAM\/C with autologous stem cell support as frontline therapy for advanced mantle cell lymphoma\u2013preliminary results from the Third Nordic MCL Phase II Study (MCL3). Blood (ASH Annual Meeting Abstracts) 2009; 114 [abstract 932].","DOI":"10.1182\/blood.V114.22.932.932"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0390","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0395","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0400","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0405","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/jco.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0410","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0415","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0420","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.leu.2404959","article-title":"Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo","volume":"22","author":"Wang","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0425","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0430","doi-asserted-by":"crossref","unstructured":"Goy A, Bernstein S, Kahl B, Djulbegovic B, Robertson M, de Vos S, et al. Durable responses with bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): updated time-to-event analysis of the multicenter PINNACLE study. Blood (ASH Annual Meeting Abstracts) 2007; 110 [abstract 125].","DOI":"10.1182\/blood.V110.11.125.125"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0435","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0440","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0445","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0450","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3816\/CLM.2001.n.003","article-title":"A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma","volume":"1","author":"Wilder","year":"2001","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0455","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/annonc\/mdh093","article-title":"Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study","volume":"15","author":"Jermann","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0460","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdl395","article-title":"Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma","volume":"18","author":"Morschhauser","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0465","doi-asserted-by":"crossref","unstructured":"Romaguera JE, Fayad LE, Wang M, Cabanillas F, Hagemeister F, McLaughlin P, et al. High (95%) response rates in relapsed\/refractory mantle cell lymphoma after R-HCVAD alternating with R-methotrexate\/cytarabine (R-M-A). Blood (ASH Annual Meeting Abstracts) 2005; 106 [abstract 2446].","DOI":"10.1182\/blood.V106.11.2446.2446"},{"issue":"18 Pt 1","key":"10.1016\/j.critrevonc.2010.09.003_bib0470","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0475","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2010.09.003_bib0480","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150","volume":"18","author":"Belch","year":"2007","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.critrevonc.2010.09.003_bib0485","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol."},{"issue":"15S","key":"10.1016\/j.critrevonc.2010.09.003_bib0490","article-title":"Phase I dose escalation study of fludarabine, bortezomib, and rituximab for relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"26","author":"Barr","year":"2008","journal-title":"J Clin Oncol (ASCO Annual Meeting Abstracts)"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0495","doi-asserted-by":"crossref","unstructured":"Gerecitano JF, Portlock C, Hamlin P, Moskowitz C, Noy A, Straus DJ, et al. A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed\/refractory indolent and mantle cell lymphomas. J Clin Oncol (ASCO Annual Meeting Abstracts) 2008; 26(15S) [abstract 8512].","DOI":"10.1200\/jco.2008.26.15_suppl.8512"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0500","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10428190902856790","article-title":"A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma\u2014long-term results of a multicenter observation study","volume":"50","author":"Weigert","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0505","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4161\/mabs.1.1.7472","article-title":"Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma","volume":"1","author":"Alinari","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0510","doi-asserted-by":"crossref","unstructured":"Goy A, Ford P, Feldman T, Pecora A, Goldberg S, Donato M, et al. A phase 1 trial of the pan bcl-2 family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed\/refractory mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2007; 110 [abstract 2569].","DOI":"10.1182\/blood.V110.11.2569.2569"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0515","doi-asserted-by":"crossref","unstructured":"Ruan J, Martin P, Furman RR, Vose JM, LaCasce A, Cheung YK, O\u2019Loughlin J, Elstrom R, Niesvizky R, Chadburn A, Ely S, Cesarman E, Coleman M, Leonard JP. CHOP-R+Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL). Blood (ASH Annual Meeting Abstracts) 2009; 114 [abstract 2682].","DOI":"10.1182\/blood.V114.22.2682.2682"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0520","doi-asserted-by":"crossref","unstructured":"Beaven A, Shea TC, Moore DT, Feldman T, Ivanova A, Ferraro M, et al. A Phase I Study of Bortezomib (Velcade\u00ae) Plus 90yttrium Labeled Ibritumomab Tiuxetan (Zevalin\u00ae) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 2008; 112 [abstract 4944].","DOI":"10.1182\/blood.V112.11.4944.4944"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0525","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0530","doi-asserted-by":"crossref","unstructured":"Ansell SM, Tang H, Kurtin P, Koenig P, Inwards DJ, Shah K, et al. A phase II study of temsirolimus (CCI-779) in combination with rituximab in patients with relapsed or refractory mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2009; 114 [abstract 1665].","DOI":"10.1182\/blood.V114.22.1665.1665"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0535","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.leu.2404471","article-title":"Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma","volume":"21","author":"Haritunians","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0540","doi-asserted-by":"crossref","unstructured":"Ogura M, Uchida T, Maruyama D, Uike N, Choi I, Ishizawa K, et al. Phase I and Pharmacokinetic (PK) Study of Everolimus (RAD001) in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 2009; 114 [abstract 1712].","DOI":"10.1182\/blood.V114.22.1712.1712"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0545","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0550","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Witzig TE, Vose JM, Reeder CB, Buckstein R, Haioun C, et al. Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results of an international study (NHL-003). Blood (ASH Annual Meeting Abstracts) 2008; 112 [abstract 262].","DOI":"10.1182\/blood.V112.11.262.262"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0555","doi-asserted-by":"crossref","unstructured":"Reeder CB, Witzig TE, Vose JM, Zinzani PL, Buckstein R, Haioun C, et al. The efficacy and safety of lenalidomide oral monotherapy in patients with mantle cell lymphoma previously treated with bortezomib: pooled data from two phase II studies (NHL-002 and NHL-003). Blood (ASH Annual Meeting Abstracts) 2008; 112 [abstract 1560].","DOI":"10.1182\/blood.V112.11.1560.1560"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0560","unstructured":"Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samanigo F, et al. Lenalidomide in combination with rituximab is effective with manageable toxicity in a phase I\/II study in relapsed\/refractory mantle cell lymphoma. Ann Oncol (ICML Meeting Abstracts) 2008; 19(Suppl. 4) [abstract 306]."},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0565","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0570","doi-asserted-by":"crossref","unstructured":"Tay K, Shapiro G, Disinski M, Chirieac LR, Pittaluga S, Jaffe ES, et al. Phase I\/II study of a hybrid schedule of flavopiridol in relapsed\/refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL). J Clin Oncol (ASCO Annual Meeting Abstracts) 2009; 27(15S) [abstract 8563].","DOI":"10.3816\/CLML.2010.n.037"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0575","doi-asserted-by":"crossref","unstructured":"Zhang L, Schafer P, Muller G, Stirling D, Bartlett B. Direct inhibitory effects of lenalidomide on the proliferation and VEGF production of non-Hodgkin lymphoma cells are associated with increased SPARC expression. Blood (ASH Annual Meeting Abstracts) 2008; 112 [abstract 2612].","DOI":"10.1182\/blood.V112.11.2612.2612"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0580","doi-asserted-by":"crossref","unstructured":"Gaidarova S, Corral LG, Gleizer E, Young D, Brady H, Bennett B, et al. Lenalidomide Enhances Anti-Tumor Effect of T Cells against Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 2008; 112 [abstract 2616].","DOI":"10.1182\/blood.V112.11.2616.2616"},{"issue":"15","key":"10.1016\/j.critrevonc.2010.09.003_bib0585","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1073\/pnas.0901166106","article-title":"E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction","volume":"106","author":"Gorgun","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"10.1016\/j.critrevonc.2010.09.003_bib0590","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0595","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/modpathol.3880556","article-title":"A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas","volume":"15","author":"Belaud-Rotureau","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0600","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0605","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0610","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2005.00546.x","article-title":"Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma","volume":"76","author":"Heider","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0615","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2005-11-026344","article-title":"Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells","volume":"110","author":"Kawamata","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0620","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1349-7006.2009.01360.x","article-title":"Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma","volume":"101","author":"Watanabe","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0625","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-007-0543-3","article-title":"Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma","volume":"61","author":"Rolland","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0630","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00280-009-1185-4","article-title":"Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed\/refractory mantle cell lymphoma: a Groupe d\u2019Etude des Lymphomes de l\u2019Adulte trial","volume":"65","author":"Rolland","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0635","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0640","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1158\/1535-7163.MCT-06-0235","article-title":"Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways","volume":"5","author":"Yu","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.critrevonc.2010.09.003_bib0645","doi-asserted-by":"crossref","unstructured":"Guidetti A, Carlo-Stella C, Devizzi L, Matteucci P, Marchian\u00f2 A, Lanocita R, et al. Preliminary Results of a Phase II Trial with the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 2009; 114 [abstract 1658].","DOI":"10.1182\/blood.V114.22.1658.1658"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842810002167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842810002167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T04:24:07Z","timestamp":1712031847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842810002167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":129,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S1040842810002167"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2010.09.003","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}